|
| |
About Us
The broad interests and
diverse experience of our Advisory Board provide
the core knowledge for gaining insights relevant to our client’s businesses.
Members often play an active role in providing services for our clients.
William B. Armiger, Ph.D.
Abram Becker
Pamela
Hicks, M.S., MBA
E. Kendall Pye,
Ph.D.
Thomas P. Sutula, M.D., Ph.D.
 |
William B. Armiger, Ph.D.,
President of BioChemInsights, has over
25 years of technical and business experience in chemicals, pharmaceuticals and
biotechnology. Dr. Armiger began his career by founding BioChem Technology as a
high-tech R&D company developing, licensing, and commercializing products and
technology for use in bioprocessing.
|
His career has included positions with Arthur
D. Little, The Catalyst Group, and most recently, as Vice President of Venture
Catalysts. Dr. Armiger has led numerous business and technical projects
relating to the development and commercial production of fine chemical and
pharmaceutical products by chemical synthesis, fermentation, cell culture, and
enzymatic processes. He has worked closely with clients identifying strategic
partners and structuring relationships for technology innovation and product
marketing within the chemical and pharmaceutical sectors. He has provided
strategic business development services in pharmaceutical fine chemicals and
biotechnology and has been involved in successful merger and acquisition
assignments with specialty chemical companies for microbial and biocatalyst
technology used for manufacturing high-value pharmaceutical intermediates.
Other recent activities have involved the development of growth strategies by
acquisition of targeted pharmaceutical fine chemical companies.
Dr. Armiger received his B.S.E. in
Chemical Engineering from Princeton University and his Ph.D. in Chemical and
Biochemical Engineering from the University of Pennsylvania.
| Abram Becker, founder of Becker &
Associates, collaborates with companies to develop new business opportunities,
and to innovate, improve, and solve process problems in pharmaceuticals,
pesticides and fine chemical products. |
Dr. Becker’s process development expertise
includes asymmetric synthesis and resolution, biocatalysis, boron chemistry,
electrochemistry, halogenation chemistry, low temperature reactions, organo-metallic
chemistry, phase transfer catalysis and super acid chemistry.
Working in industry since1966, Dr. Becker
has held Scientific Director and R&D managemt positions with Isochem, Lafon’s
pharmaceuticals division, and SA Druggest. His industrial experience has
resulted in processes for over eighty intermediates, fine-chemicals,
pharmaceuticals and generics including alkaloids and steroids, terpenes,
heterocyclic psychotropic drugs, amino acids, cyclicpolypeptides, and other
specialties. Throughout his career Dr. Becker has obtained more than 30 patents.
Dr. Becker received his M. Sc. degree in
organic chemistry form the Hebrew University of Jerusalem and his D. Sc. From
the College de France, University of Paris1964.
|
Pamela
Hicks, M.S., MBA,
founder of Venturesources, provides market
research, technology assessment, strategy, business development and due
diligence services for new ventures in pharmaceuticals and biotechnology. Ms.
Hicks brings a unique blend of pharmaceutical and diagnostic knowledge combining
practical business experience with a biomedical foundation. Her experience
includes helping clients make internal and external investment decisions in
therapeutic areas including oncology, osteoporosis, rheumatology, anti-inflammatories,
gene therapy, therapeutic vaccines, cellular therapies and women’s health.
|
With more than ten years in pharmaceutical
and diagnostic marketing and business development with Centocor and five years
in corporate planning and discovery research with Monsanto and Rohm & Haas, her
accomplishments include selection of pharmaceutical new product programs and
acquisition and licensing candidates; negotiating over 50 agreements in
oncology, inflammatory and autoimmune diseases, antibody engineering, and
genetic vaccines; and leading successful acquisition searches.
Her educational background includes an MBA
from the Wharton School of the University of Pennsylvania, and MS in Genetics
from the University of Missouri, and a BS in Biology from Chatham College, where
she was elected to Phi Beta Kappa.
|
E. Kendall Pye, Ph.D.,
former President and CEO of Repap
Technologies, Inc and Vice-President, Science and Technology, Repap
Enterprises. In 1981, Dr. Pye was recruited by General Electric venture capital
as President and CEO of the start-up biotechnology venture, Biological Energy
Corporation. This company developed a precursor technology to the Alcell process
and was acquired by Repap Enterprises. Apart from his management and corporate
duties, Dr. Pye led the research and marketing programs on bioactive compounds
and materials recovered from the $60 million Alcell demonstration plant.
|
As a faculty member in Biochemistry at the
University of Pennsylvania School of Medicine from 1965-81, his research
interests included biological oscillations, microbial metabolism and its
control, immobilized enzyme technology and enzyme kinetics. Over his
professional career in biochemistry, biophysics and biotechnology, Dr. Pye has
authored over 100 publications, received several patents, and edited several
conference proceedings. He represented the United States as a delegate in
scientific exchange missions to Japan, NATO, and the Soviet Union. He has
served on industry and technical association boards and is a member of several
professional societies.
Dr. Pye received his B.Sc. and Ph.D. in
biochemistry from the University of Manchester, Institute for Science and
Technology and completed a Post-Doctoral Fellowship with Dr. Britton Chance at
the University of Pennsylvania in biophysics, studying metabolic control
phenomena.
|
Thomas P. Sutula, M.D., Ph.D.,
Detling Professor and Chairman, Department of Neurology at the University of
Wisconsin, and Director for the Center for Neuroscience at the University of
Wisconsin. He was previously Director of the Comprehensive Epilepsy Program and
Director of Electroencephalography at the University of Wisconsin Hospital. He
maintains an active basic research program as well as a clinical practice
specializing in seizure disorders. Dr. Sutula's work in neural plasticity and
epilepsy has attracted international attention, and he is regarded as an
authority on neural plasticity associated with epilepsy and memory disorders.
|
Prof. Sutula serves on several national
medical committees at NIH, sits on the editorial boards of three scientific
journals, reviews numerous manuscripts for over 20 journals, and has published
over 80 scientific papers and abstracts in peer-reviewed journals. Prof. Sutula
participates in numerous steering committees at the University of Wisconsin and
University Hospital, several of which he has chaired.
Dr. Sutula is board certified in internal
medicine, neurology and psychiatry. He is active in professional societies
including the American Academy of Neurology, Society for Neuroscience and the
American Epilepsy Society. He will serve as President of the American Epilepsy
Society in 2002.
He received an AB in Chemistry magna cum
laude from Princeton University in 1971, an MD from the University of
Pennsylvania in 1975 and a PhD in Neuroscience from the University of Virginia
Medical School in 1985. He has received numerous academic honors including Phi
Beta Kappa, Sigma Xi, and Alpha Omega Alpha.
|
